Kyle Doherty

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Adjuvant ribociclib plus an aromatase inhibitor was safe and displayed long-term efficacy in hormone receptor–positive, HER2-negative early breast cancer.

The EMA’s CHMP has recommended the approval of adjuvant cemiplimab in CSCC at high risk of recurrence after surgery and radiation

Acalabrutinib plus lenalidomide and rituximab displayed activity and had a tolerable safety profile in first-line follicular lymphoma.

Maintenance rucaparib showed efficacy in recurrent/metastatic endometrial cancer after the completion of first- or second-line chemotherapy.

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

Abemaciclib was safe and active for the treatment of patients with HIV-associated and -negative Kaposi sarcoma.

Kanwal P.S. Raghav, MBBS, MD, discusses the role of fruquintinib for the treatment of patients with later-line colorectal cancer.

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.

Benjamin P. Levy, MD, FASCO, discusses how new targeted approaches are affecting the NSCLC treatment landscape.

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

Dato-DXd displayed topline survival benefits in patients with recurrent/metastatic TNBC who could not receive immunotherapy.

Martin F. Dietrich, MD, PhD, discusses the potential role of atebimetinib plus chemotherapy in frontline pancreatic cancer.

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

AMXT 1501 plus difluoromethylornithine has received orphan drug designation from the FDA in patients with neuroblastoma.

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

Kashyap Patel MD, ABIM, BCMAS, discusses the present challenges with integrating AI tools into community practice.

Jim Chen, MD, discusses how artificial intelligence can aid community oncologists in providing optimal care.

Jennifer A. Woyach, MD, discusses the potential of pirtobrutinib as a second-line option for patients with CLL.

Dana M. Chase, MD, discusses the effect of the frontline dostarlimab plus chemotherapy on the recurrent endometrial cancer landscape.

A panel of hematologic cancer experts discusses data on GVHD management from the 2025 SOHO Annual Meeting.

Asad Dean, MD, discusses the evolving role of pirtobrutinib in chronic lymphocytic leukemia.

IberDd improved MRD negativity rates vs DVd in patients with relapsed/refractory multiple myeloma.

Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Vorasidenib has been approved by the European Commission for IDH1/2-mutated grade 2 glioma.

Naoto T. Ueno, MD, PhD, FACP, discusses treatment sequencing considerations in HER2+ advanced or metastatic breast cancer.